Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated. @RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9